Lista de obras - Tara C Gangadhar - Dominio Público Uruguay

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

article

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

artículo científico publicado en 2016

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

artículo científico publicado en 2017

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors

artículo científico publicado en 2017

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

article

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

artículo científico publicado en 2014

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

artículo científico publicado en 2017

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

artículo científico publicado en 2016

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

artículo científico publicado en 2015

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

article

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.

artículo científico publicado en 2015

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

artículo científico publicado en 2016

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

artículo científico publicado en 2015

Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate

artículo científico publicado en 2017

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

scientific article published on 01 December 2018

Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.

artículo científico publicado en 2016

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

artículo científico publicado en 2017

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

artículo científico publicado en 2017

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

article

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models

artículo científico publicado en 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

artículo científico publicado en 2016

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

artículo científico publicado en 2018

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma

artículo científico publicado en 2017

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

artículo científico publicado en 2017

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research ⬇️

artículo científico publicado el 22 de enero de 2011

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

artículo científico publicado en 2017

Improving the Safety of Oral Chemotherapy at an Academic Medical Center

artículo científico publicado en 2016

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

article

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.

artículo científico publicado en 2018

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

scholarly article by David L Bajor et al published 2018 in OncoImmunology

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Mitigating the toxic effects of anticancer immunotherapy

artículo científico

Molecular markers to individualize adjuvant therapy for colon cancer

artículo científico publicado en 2010

Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases

artículo científico publicado en 2015

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

article

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

artículo científico publicado en 2014

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

artículo científico publicado en 2015

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

artículo científico publicado en 2012

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

artículo científico publicado en 2015

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

artículo científico publicado en 2016

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

artículo científico publicado en 2011

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

artículo científico publicado en 2015

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

artículo científico publicado en 2016

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

artículo científico publicado en 2013

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

artículo científico publicado en 2017

Takotsubo cardiomyopathy in a patient with esophageal cancer: a case report

artículo científico publicado en 2008

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

artículo científico publicado en 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.

artículo científico publicado en 2015

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

artículo científico publicado en 2016

The role of chemokine receptor CXCR4 in lung cancer

scientific article published on 18 March 2010

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

artículo científico publicado en 2011

Treatment options for metastatic melanoma in solid organ transplant recipients

artículo científico publicado en 2015

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

artículo científico publicado en 2016

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

artículo científico publicado en 2011

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.

artículo científico publicado en 2014

Lista de obras de Tara C Gangadhar

140 Relationship between programmed death ligand 1 (PD-L1) expression and clinical outcome in patients (pts) with melanoma (MEL) treated with pembrolizumab (pembro; MK-3475)

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors

Abstract CT104: Antitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma(MEL): Correlation of tumor PD-L1 expression with outcome

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Broad Applicability of Nivolumab in Melanoma Regardless of BRAF Mutation Status.

Clinical Cancer Advances 2016: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types

Complete Response of Advanced Melanoma Treated With Talimogene Laherparepvec and Subsequent Sweet's-like Infiltrate

Correction: Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

Cutaneous autoimmune effects in the setting of therapeutic immune checkpoint inhibition for metastatic melanoma.

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program.

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

Enhancing the evaluation of PI3K inhibitors through 3D melanoma models

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

FREQUENT SUBCLINICAL MACULAR CHANGES IN COMBINED BRAF/MEK INHIBITION WITH HIGH-DOSE HYDROXYCHLOROQUINE AS TREATMENT FOR ADVANCED METASTATIC BRAF MUTANT MELANOMA: Preliminary Results From a Phase I/II Clinical Treatment Trial

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma

Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research ⬇️

Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines

Improving the Safety of Oral Chemotherapy at an Academic Medical Center

LBA34PEMBROLIZUMAB (PEMBRO; MK-3475) FOR ADVANCED MELANOMA (MEL): RANDOMIZED COMPARISON OF TWO DOSING SCHEDULES

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma.

Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

Mitigating the toxic effects of anticancer immunotherapy

Molecular markers to individualize adjuvant therapy for colon cancer

Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases

P0116 Updated clinical efficacy of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients with melanoma

Patterns of response in patients with advanced melanoma treated with Pembrolizumab (MK-3475) and evaluation of immune-related response criteria (irRC).

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma

Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Proteomic characterization of non-small cell lung cancer in a comprehensive translational thoracic oncology database

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

Takotsubo cardiomyopathy in a patient with esophageal cancer: a case report

Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma.

The efficacy of anti-PD-1 agents in acral and mucosal melanoma

The role of chemokine receptor CXCR4 in lung cancer

The role of the c-Met pathway in lung cancer and the potential for targeted therapy

Treatment options for metastatic melanoma in solid organ transplant recipients

Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade

Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.